Abbott Laboratories (ABT) financial statements

+71.1%since 2007
FY2025 revenue
$44.3B▲ +5.7%
FY2025 net income
$6.5B▼ −51.3%
FY2025 diluted EPS
$3.72▼ −51.3%
FY2025 free cash flow
$7.4B▲ +16.4%

Abbott Laboratories income statement

Abbott Laboratories income statement
USD millionsFY2025FY2024FY2023
Period ended31 Dec 202531 Dec 202431 Dec 2023
Revenue44,32841,95040,109
Operating income8,0536,8256,478
Pretax income8,4667,0136,664
Net income6,52413,4025,723
Diluted earnings per share3.727.643.26

Abbott Laboratories balance sheet

Abbott Laboratories balance sheet
USD millionsFY2025FY2024FY2023
Period ended31 Dec 202531 Dec 202431 Dec 2023
Cash and cash equivalents8,5227,6166,896
Total assets86,71381,41473,214
Total liabilities (derived)33,94233,51334,387
Total equity52,77147,90138,827
Long-term debt9,89612,62513,599

Abbott Laboratories cash flow statement

Abbott Laboratories cash flow statement
USD millionsFY2025FY2024FY2023
Period ended31 Dec 202531 Dec 202431 Dec 2023
Operating cash flow9,5668,5587,261
Capital expenditure-2,171-2,207-2,202
Free cash flow (derived)7,3956,3515,059
Dividends paid-4,116-3,836-3,556
Share repurchases-893-1,295-1,227

Quarterly highlights

Quarterly highlights
USD millionsQ3 FY2026Q2 FY2026Q1 FY2026Q4 FY2025
Period ended30 Sep 202630 Jun 202631 Mar 202631 Dec 2025
Revenue (derived)13,01312,59311,16411,459
Operating income (derived)1,3581,6931,3452,251
Net income (derived)9209281,0771,776
Diluted earnings per share0.530.530.61n/a
Operating cash flow (derived)1,7372,4881,3153,315
Total assets108,247109,215110,42986,713

Abbott Laboratories major shareholders

Abbott Laboratories major shareholders
HolderShare of classSharesFiled
Vanguard Capital Management7.5%130,676,77629 April 2026

Abbott Laboratories 10-K and SEC filings

Abbott Laboratories 10-K and SEC filings
FiledFormTypeDescription
4 November 202610-QQuarterly reportQuarterly report
21 October 20268-KCurrent reportFORM 8-K
21 October 20268-KCurrent reportCurrent report
20 August 20268-KCurrent reportFORM 8-K
28 July 202610-QQuarterly reportQuarterly report
16 July 20268-KCurrent reportCurrent report
29 April 202610-QQuarterly reportQuarterly report
27 April 20268-KCurrent reportFORM 8-K

Common questions

What was Abbott Laboratories' revenue in fiscal 2025?

Abbott Laboratories reported $44.3 billion in revenue for fiscal 2025, the year ended 31 December 2025, up 5.7% from fiscal 2024.

What was Abbott Laboratories' net income in fiscal 2025?

Abbott Laboratories reported net income of $6.5 billion for fiscal 2025, the year ended 31 December 2025, down 51.3% from fiscal 2024. Diluted earnings per share were $3.72.

What was Abbott Laboratories' free cash flow in fiscal 2025?

Abbott Laboratories had $7.4 billion in free cash flow in fiscal 2025. Operating cash flow was $9.6 billion and capital expenditure was $2.2 billion.

What were Abbott Laboratories' total assets at the end of fiscal 2025?

Abbott Laboratories reported total assets of $86.7 billion at the end of fiscal 2025, the year ended 31 December 2025.

How much Abbott Laboratories history do I get?

Every account gets the full history, annual and quarterly, with first reported values and as of dates.